The Diagnostic Significance of Coapplying a Rabeprazole Test with the SF-36 for Gastroesophageal Reflux Disease

Table 4

Comparison of improving SF-36 rate between GERD and non-GERD patients after one-week and two-week therapy.

	One week after therapy (%)			Two weeks after therapy (%)
			𝑃 value			𝑃 value
	GERD	Non-GERD		GERD	Non-GERD
A group	28.32±25.78	2.26±3.68	0.006	40.66±43.87	8.24±6.85	0.037
B group	36.22±27.60	13.63±6.38	>0.05	45.58±35.25	16.76±8.83	>0.05
C group	25.22±17.43	16.13±18.62	>0.05	42.35±29.46	24.07±31.62	>0.05